Free Trial
NASDAQ:SNY

Sanofi (SNY) Stock Price, News & Analysis

Sanofi logo
$52.88
-0.57 (-1.07%)
(As of 10/31/2024 ET)

About Sanofi Stock (NASDAQ:SNY)

Key Stats

Today's Range
$52.40
$52.99
50-Day Range
$52.05
$58.53
52-Week Range
$45.00
$58.97
Volume
1.40 million shs
Average Volume
2.04 million shs
Market Capitalization
$134.20 billion
P/E Ratio
26.98
Dividend Yield
2.78%
Price Target
$57.50
Consensus Rating
Moderate Buy

Company Overview

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
46th Percentile Overall Score

SNY MarketRank™: 

Sanofi scored higher than 46% of companies evaluated by MarketBeat, and ranked 683rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sanofi has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sanofi has only been the subject of 1 research reports in the past 90 days.

  • Read more about Sanofi's stock forecast and price target.
  • Earnings Growth

    Earnings for Sanofi are expected to grow by 13.18% in the coming year, from $4.25 to $4.81 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sanofi is 26.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.66.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sanofi is 26.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.59.

  • Price to Earnings Growth Ratio

    Sanofi has a PEG Ratio of 1.55. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Sanofi has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sanofi's valuation and earnings.
  • Percentage of Shares Shorted

    0.32% of the float of Sanofi has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanofi has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Sanofi has recently decreased by 11.60%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sanofi pays a meaningful dividend of 2.72%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Sanofi does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Sanofi is 75.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Sanofi will have a dividend payout ratio of 30.56% next year. This indicates that Sanofi will be able to sustain or increase its dividend.

  • Read more about Sanofi's dividend.
  • Percentage of Shares Shorted

    0.32% of the float of Sanofi has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanofi has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Sanofi has recently decreased by 11.60%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Sanofi has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 29 news articles for Sanofi this week, compared to 11 articles on an average week.
  • Search Interest

    13 people have searched for SNY on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Sanofi to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sanofi insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.00% of the stock of Sanofi is held by insiders.

  • Percentage Held by Institutions

    Only 10.04% of the stock of Sanofi is held by institutions.

  • Read more about Sanofi's insider trading history.
Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Stock News Headlines

Sanofi’s Dupixent Shows Promise for Skin Disorder
Leerink Partnrs Has Negative Outlook of Sanofi Q4 Earnings
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Sanofi says Beyfortus to be broadly available in more Canadian territories soon
Q3 2024 Sanofi SA Earnings Call Transcript
Why Sanofi Stock Flew Higher on Friday
See More Headlines

SNY Stock Analysis - Frequently Asked Questions

Sanofi's stock was trading at $49.73 on January 1st, 2024. Since then, SNY stock has increased by 6.3% and is now trading at $52.88.
View the best growth stocks for 2024 here
.

Sanofi (NASDAQ:SNY) issued its quarterly earnings data on Friday, October, 25th. The company reported $1.57 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. Sanofi's revenue was up 12.3% on a year-over-year basis.

Sanofi subsidiaries include Kiadis Pharma, Principia BioPharma, Synthorx, Ablynx, Bioverativ, Aventis S.A., Ablynx N.V., and more.

Top institutional shareholders of Sanofi include Raymond James & Associates (0.11%), Van ECK Associates Corp (0.02%), Janney Montgomery Scott LLC (0.01%) and Foundation Resource Management Inc. (0.01%).
View institutional ownership trends
.

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sanofi investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
10/25/2024
Today
10/31/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNY
Employees
86,088
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$57.50
High Stock Price Target
$60.00
Low Stock Price Target
$55.00
Potential Upside/Downside
+8.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$5.84 billion
Pretax Margin
12.84%

Debt

Sales & Book Value

Annual Sales
$48.86 billion
Cash Flow
$6.22 per share
Book Value
$31.81 per share

Miscellaneous

Outstanding Shares
2,537,829,000
Free Float
2,512,451,000
Market Cap
$134.20 billion
Optionable
Optionable
Beta
0.60

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:SNY) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners